Compare › semaglutide vs orforglipron
semaglutide vs orforglipron
Both semaglutide and orforglipron are approved in the US, so the useful differences between them are which conditions each is approved for and what is still under study. semaglutide has 405 trials on file here and orforglipron 27, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| semaglutide | orforglipron | |
|---|---|---|
| Status | marketed | phase3 |
| Target | GLP-1 | GLP-1 (oral small molecule) |
| Route | SC/oral | oral |
| Sponsor | Novo Nordisk | Eli Lilly |
| US brand names | OZEMPIC, RYBELSUS, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HD | FOUNDAYO |
| First FDA approval | 2017-12-05 | 2026-04-01 |
| EU authorisation | Ozempic, Rybelsus, Wegovy | Not authorised |
| FDA actions on file | 51 | 2 |
| Active trials | 203 | 19 |
| Active phase 3 | 72 | 17 |
| Participants enrolled | 94,274 | 21,378 |
| Results scheduled | 76 | 14 |
| Supply records | 3 | 0 |
Where they are being studied
Both: Cardiovascular disease; Chronic kidney disease; Hypertension; Obesity & overweight; Prediabetes; Type 2 diabetes
semaglutide only: Alcohol use disorder; Atrial fibrillation; Cancer; Diabetes (unspecified); Diabetic kidney disease; Heart failure; MASH / NAFLD; Metabolic syndrome; Neurodegenerative disease; Obstructive sleep apnea; Polycystic ovary syndrome; Psychiatric conditions; Substance use; Type 1 diabetes
orforglipron only: Osteoarthritis